Trial Profile
Dose Tolerability Study With High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs House dust mite allergy immunotherapy subcutaneous HAL Allergy (Primary)
- Indications Allergic rhinitis; Asthma; Rhinoconjunctivitis
- Focus Adverse reactions
- 05 Nov 2010 Actual end date (Aug 2010) added as reported by ClinicalTrials.gov.
- 05 Nov 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Sep 2009 New trial record